Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.

Trial Profile

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Belimumab (Primary) ; Mycophenolate mofetil
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 13 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 17 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016, according to ClinicalTrials.gov record.
    • 18 Mar 2015 Planned End Date changed from 1 Aug 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top